ArticleProbiotics and antimicrobial proteins2022
Safety Evaluation of Lactobacillus delbrueckii subsp. lactis CIDCA 133: a Health-Promoting Bacteria.
Article in Probiotics and antimicrobial proteins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Genomic Insights Into the Probiotic and Safety Attributes of Pediococcus acidilactici BC-7 for its Potential Application in Livestock Health.Probiotics and antimicrobial proteins · 2026Article
- Safety and immunostimulatory potential evaluation of Limosilactobacillus fermentum isolated from millet-based fermented food in mice.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Review
- Studies on the Probiotic, Adhesion, and Induction Properties of Artisanal Lactic Acid Bacteria: to Customize a Gastrointestinal Niche to Trigger Anti-obesity Functions.Probiotics and antimicrobial proteins · 2025Article
- New generation probiotics: combining probiotic and biotechnological potential of Kluyveromyces marxianus.Applied microbiology and biotechnology · 2025Article
- A NovelMicroorganisms · 2025Article
- Potential Probiotic Properties and Complete Genome Analysis ofMicroorganisms · 2024Article
- Multidrug resistance profile in Lactobacillus delbrueckii: a food industry species with probiotic properties.World journal of microbiology & biotechnology · 2024Review
- Recombinant probioticFrontiers in microbiology · 2024Article
- Genomic analysis and functional properties ofFrontiers in microbiology · 2024Article
- Characterization of a Potential ProbioticJournal of microbiology and biotechnology · 2023Article
- Lactic acid bacteria isolated from Chinese traditional fermented milk as novel probiotic strains and their potential therapeutic applications.3 Biotech · 2022Article
- Probiotic ofFoods (Basel, Switzerland) · 2022Article
- Paraprobiotics and Postbiotics ofMicroorganisms · 2022Article
- Genomic Characterization ofFrontiers in bioinformatics · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactobacillus delbrueckii subsp. lactis CIDCA is a new potential probiotic strain whose molecular basis attributed to the host's benefit has been reported. This study investigated the safety aspects of Lactobacillus delbrueckii subsp. lactis CIDCA 133 based on whole-genome sequence and phenotypic analysis to avoid future questions about the harmful effects of this strain consumption. Genomic analysis showed that L. delbrueckii subsp. lactis CIDCA 133 harbors virulence, harmful metabolites, and antimicrobial resistance-associated genes. However, none of these genetic elements is flanked or located within prophage regions and plasmid sequence. At a phenotypic level, it was observed L. delbrueckii subsp. lactis CIDCA 133 antimicrobial resistance to aminoglycosides streptomycin and gentamicin antibiotics, but no hemolytic and mucin degradation activity was exhibited by strain. Furthermore, no adverse effects were observed regarding mice clinical and histopathological analysis after the strain consumption (5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.